๐
Nyxthracis (previously Obiltoxaximab SFL)
obiltoxaximab
Anthrax
๐ซ Withdrawn
โ
No active alerts
This medicine has no ongoing shortages, safety letters or recalls.
What it's used for
Obiltoxaximab SFL is indicated in combination with appropriate antibacterial drugs in all age groups for treatment of inhalational anthrax due to Bacillus anthracisย (see section 5.1). Obiltoxaximab SFL is indicated in all age groups for post-exposure prophylaxis of inhalational anthrax when alternative therapies are not appropriate or are not available (see section 5.1).
โ ๏ธ Patient safety
No
Official EMA page
https://www.ema.europa.eu/en/medicines/human/EPAR/nyxthracis